At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLXN Silexion Therapeutics Corp
Trading 05-13 15:38:35 EDT
0.5600
-0.0190
-3.28%
High0.5990Low0.5393Vol138.65K
Open0.5950D1 Closing0.5790Amplitude10.31%
Mkt Cap2.28MTradable Cap2.26MTotal Shares4.07M
T/O77.60KT/O Rate3.43%Tradable Shares4.04M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204
TIPRANKS  ·  00:35
Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204
Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer
Reuters  ·  05-13 20:05
Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer
Silexion Therapeutics Announces Initiation of Gmp Clinical Supply Manufacturing of Sil204 With Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
THOMSON REUTERS  ·  05-13 20:00
Silexion Therapeutics Announces Initiation of Gmp Clinical Supply Manufacturing of Sil204 With Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)
TIPRANKS  ·  04-29
Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)
Silexion Therapeutics submits SIL204 clinical trial application to Germany
TIPRANKS  ·  04-28
Silexion Therapeutics submits SIL204 clinical trial application to Germany
Silexion submits Germany trial application for SIL204 pancreatic cancer study
Reuters  ·  04-28
Silexion submits Germany trial application for SIL204 pancreatic cancer study
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s Bfarm for Sil204 in Kras-Driven Locally Advanced Pancreatic Cancer
THOMSON REUTERS  ·  04-28
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s Bfarm for Sil204 in Kras-Driven Locally Advanced Pancreatic Cancer
Silexion Therapeutics removes Ilan Levin from board; change effective immediately
Reuters  ·  03-26
Silexion Therapeutics removes Ilan Levin from board; change effective immediately
Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204
TIPRANKS  ·  03-24
Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204
Silexion Therapeutics Corp: Expects to Initiate Human Clinical Trials in Q2 of 2026
THOMSON REUTERS  ·  03-24
Silexion Therapeutics Corp: Expects to Initiate Human Clinical Trials in Q2 of 2026
Silexion Therapeutics: to Submit Phase 2/3 Clinical Trial Application in Germany by Qtr-End, Extra Regulatory Filings Across EU in Early 2027
THOMSON REUTERS  ·  03-24
Silexion Therapeutics: to Submit Phase 2/3 Clinical Trial Application in Germany by Qtr-End, Extra Regulatory Filings Across EU in Early 2027
Silexion Therapeutics Receives Approval From Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer
THOMSON REUTERS  ·  03-24
Silexion Therapeutics Receives Approval From Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer
Israeli Health Ministry clears Silexion Phase 2/3 trial of SIL204 in pancreatic cancer
Reuters  ·  03-24
Israeli Health Ministry clears Silexion Phase 2/3 trial of SIL204 in pancreatic cancer
Silexion Therapeutics reconvened shareholder meeting with 36.6% of shares represented
Reuters  ·  03-24
Silexion Therapeutics reconvened shareholder meeting with 36.6% of shares represented
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and Silexion Therapeutics (SLXN)
TIPRANKS  ·  03-19
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and Silexion Therapeutics (SLXN)
Press Release: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Dow Jones  ·  03-18
Press Release: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Silexion Therapeutics FY 2025 net loss narrows 27.9% to USD 11.91 million
Reuters  ·  03-18
Silexion Therapeutics FY 2025 net loss narrows 27.9% to USD 11.91 million
Silexion Therapeutics Corp. Announces Date for Extraordinary General Meeting
Reuters  ·  02-14
Silexion Therapeutics Corp. Announces Date for Extraordinary General Meeting
Silexion Therapeutics unveils siRNA approach targeting KRAS mutations in pancreatic and other cancers
Reuters  ·  02-03
Silexion Therapeutics unveils siRNA approach targeting KRAS mutations in pancreatic and other cancers
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
Reuters  ·  01-21
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Introduction

Company Name.
Silexion Therapeutics Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Moringa Acquisition Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company focuses on pursuing opportunities in technology-based businesses or industries in Israel. Moringa Acquisition Corp was incorporated in 2020 and is based in New York, New York.
Issue price:
--